Germantown, Md.-based Neuralstem is involved in a Phase 1 human clinical trial testing the safety and feasibility of using NSI-566 spinal cord-derived neural stem cells to repair chronic spinal cord injury.
A biopharmaceutical company, Neuralstem develops nervous system therapies derived from neural stem cell technology.
Here are six takeaways:
1. NSI-566 represents the company's lead stem cell therapy candidate.
2. University of California San Diego serves as the study site, and just added a new cohort of four patients.
3. The four new patients all have AIS-A complete, quadriplegic, cervical injuries involving C5-C7 cord.
4. The patients suffered the injury one to two years before undergoing stem cell treatment.
5. The treatment involves six injections of NSI-566 into the spinal cord's affected area.
6. UCSD researchers are analyzing long-term safety data from the study's first cohort on chronic complete thoracic injuries.